Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 2,269,284 shares, a growth of 21.6% from the November 30th total of 1,866,304 shares. Based on an average trading volume of 971,311 shares, the days-to-cover ratio is currently 2.3 days. Currently, 3.0% of the company’s shares are sold short.

A number of research firms have recently issued reports on ATNM. Maxim Group set a $3.00 target price on Actinium Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 12th. B. Riley began coverage on Actinium Pharmaceuticals in a research note on Wednesday, December 6th. They issued a “buy” rating and a $2.75 target price for the company. Roth Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Finally, Zacks Investment Research upgraded Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research note on Monday, December 25th. Five analysts have rated the stock with a buy rating, Actinium Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $3.75.

Shares of Actinium Pharmaceuticals (NYSEAMERICAN ATNM) opened at $0.66 on Monday. Actinium Pharmaceuticals has a 12 month low of $0.54 and a 12 month high of $1.72. The stock has a market capitalization of $53.00, a PE ratio of -1.40 and a beta of 41.36.

COPYRIGHT VIOLATION WARNING: “Actinium Pharmaceuticals Inc (ATNM) Sees Significant Increase in Short Interest” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.